Short Bowel Syndrome (SBS) Market Size, Share and Growth Outlook 2026: By Therapy Type, By Patient Demographics, By Distribution Channel, Companies to 2034
The global Short Bowel Syndrome (SBS) Market size is forecast to increase from $2.86 Billion in 2026 to $12.46 Billion in 2034 at a CAGR of 20.2% between 2026 and 2034.
The Short Bowel Syndrome market report provides detailed analysis and outlook of Short Bowel Syndrome segments including By Therapy Type (Nutritional Support, Pharmacological Therapeutics, GLP-2 Analogs, Growth Hormones, Symptomatic Treatment Drugs, Surgical Interventions ), By Patient Demographics (Pediatric Patients, Adult Patients), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Specialty Drugstores, Online / E-pharmacies) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.
Short Bowel Syndrome (SBS) Industry Overview
GLP-2 Analog Innovation, Improved Patient Outcomes, and Expanded Treatment Access Are Transforming the Short Bowel Syndrome Industry
The short bowel syndrome (SBS) industry is undergoing significant advancement driven by innovations in glucagon-like peptide-2 (GLP-2) therapies, increased understanding of intestinal rehabilitation, and growing recognition of the substantial burden associated with long-term parenteral nutrition dependence. Healthcare providers and pharmaceutical companies are increasingly focused on developing therapies that improve intestinal absorption, reduce complications associated with intravenous support, and enhance quality of life for patients with short bowel syndrome and intestinal failure. Advances in peptide therapeutics, supportive care strategies, and reimbursement policies are reshaping treatment paradigms and expanding access to specialized therapies.
Expanded Reimbursement and Access Programs Are Improving Patient Care
Access to advanced therapies remains a critical factor influencing outcomes for patients with short bowel syndrome who require long-term nutritional support. Governments, payers, and healthcare systems are increasingly recognizing the clinical and economic benefits associated with therapies that reduce dependence on parenteral nutrition and intravenous fluids. This trend is reflected by the inclusion of Takeda Canada's REVESTIVE® (teduglutide) within the BC PharmaCare reimbursement framework for eligible pediatric and adult patients with short bowel syndrome. Expanded reimbursement access for GLP-2 analog therapies supports broader adoption of intestinal rehabilitation strategies aimed at improving patient independence and reducing treatment-related complications.
Real-World Evidence Is Highlighting the Burden of Intestinal Failure
The management of short bowel syndrome continues to be challenged by significant clinical complications associated with long-term parenteral support, including infections, metabolic disturbances, and impaired quality of life. Increasing emphasis is being placed on collecting real-world evidence to better characterize patient experiences and identify unmet therapeutic needs. Findings presented by Ironwood Pharmaceuticals at Digestive Disease Week highlighted the substantial burden experienced by patients with short bowel syndrome and intestinal failure, with healthcare providers identifying central line infections, fatigue, and abdominal pain among the most significant challenges. These findings reinforce the urgent need for more effective therapies capable of reducing dependence on chronic supportive interventions.
Next-Generation GLP-2 Therapies Are Reshaping Future Treatment Paradigms
The development of next-generation GLP-2 analog therapies represents one of the most important areas of innovation within the short bowel syndrome market. Pharmaceutical companies are focusing on therapies designed to deliver improved efficacy, longer duration of action, and more convenient dosing schedules compared with existing treatment options. Companies including Ironwood Pharmaceuticals and Zealand Pharma continue to advance novel GLP-2 analogs such as apraglutide and glepaglutide through clinical development programs. These therapies are being positioned as potentially transformative treatment options for patients with short bowel syndrome and intestinal failure by offering enhanced intestinal adaptation benefits alongside reduced treatment burden through less frequent dosing schedules.
Short Bowel Syndrome Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities
The global Short Bowel Syndrome market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Takeda Pharmaceutical Company Limited, Ironwood Pharmaceuticals, Inc. (VectivBio), Zealand Pharma A/S, Hanmi Pharm Co., Ltd., Napo Therapeutics (Jaguar Health), Nestl? S.A., Pfizer Inc., Sanofi S.A., Baxter International Inc., B. Braun Melsungen AG. The Short Bowel Syndrome market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Short Bowel Syndrome industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-
Leading companies in Short Bowel Syndrome industry include- Takeda Pharmaceutical Company Limited, Ironwood Pharmaceuticals, Inc. (VectivBio), Zealand Pharma A/S, Hanmi Pharm Co., Ltd., Napo Therapeutics (Jaguar Health), Nestl? S.A., Pfizer Inc., Sanofi S.A., Baxter International Inc., B. Braun Melsungen AG. The Short Bowel Syndrome market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.
What to expect in US Short Bowel Syndrome Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034
The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Short Bowel Syndrome market remains one of the strongest-performing segments in the country.
The US Short Bowel Syndrome Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Short Bowel Syndrome market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Short Bowel Syndrome industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.
Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Short Bowel Syndrome markets
Canada's strong Short Bowel Syndrome sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Short Bowel Syndrome market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.
Germany Short Bowel Syndrome Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.
Germany continues to remain the largest Short Bowel Syndrome market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Short Bowel Syndrome population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Short Bowel Syndrome industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Short Bowel Syndrome market outlook.
France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Short Bowel Syndrome sales through 2034
France Short Bowel Syndrome companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.
UK Short Bowel Syndrome Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain
Small high-need consumer segments remain key priority of Short Bowel Syndrome distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.
China Short Bowel Syndrome Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years
China Short Bowel Syndrome market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Short Bowel Syndrome industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Short Bowel Syndrome industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.
India Short Bowel Syndrome Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India
Indian Short Bowel Syndrome market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.
Brazil Short Bowel Syndrome market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities
Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.
Middle East and Africa Short Bowel Syndrome Industry Trends and Perspectives to 2034
According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.
Short Bowel Syndrome Market Segmentation
By Therapy Type
Nutritional Support
Pharmacological Therapeutics
GLP-2 Analogs
Growth Hormones
Symptomatic Treatment Drugs
Surgical Interventions
By Patient Demographics
Pediatric Patients
Adult Patients
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies and Specialty Drugstores
Online / E-pharmacies
Leading Companies in Short Bowel Syndrome Industry (2026)
Takeda Pharmaceutical Company Limited
Ironwood Pharmaceuticals, Inc. (VectivBio)
Zealand Pharma A/S
Hanmi Pharm Co., Ltd.
Napo Therapeutics (Jaguar Health)
Nestl? S.A.
Pfizer Inc.
Sanofi S.A.
Baxter International Inc.
B. Braun Melsungen AG
Countries Included
The Short Bowel Syndrome market report provides detailed analysis and outlook of Short Bowel Syndrome segments including By Therapy Type (Nutritional Support, Pharmacological Therapeutics, GLP-2 Analogs, Growth Hormones, Symptomatic Treatment Drugs, Surgical Interventions ), By Patient Demographics (Pediatric Patients, Adult Patients), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Specialty Drugstores, Online / E-pharmacies) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.
Short Bowel Syndrome (SBS) Industry Overview
GLP-2 Analog Innovation, Improved Patient Outcomes, and Expanded Treatment Access Are Transforming the Short Bowel Syndrome Industry
The short bowel syndrome (SBS) industry is undergoing significant advancement driven by innovations in glucagon-like peptide-2 (GLP-2) therapies, increased understanding of intestinal rehabilitation, and growing recognition of the substantial burden associated with long-term parenteral nutrition dependence. Healthcare providers and pharmaceutical companies are increasingly focused on developing therapies that improve intestinal absorption, reduce complications associated with intravenous support, and enhance quality of life for patients with short bowel syndrome and intestinal failure. Advances in peptide therapeutics, supportive care strategies, and reimbursement policies are reshaping treatment paradigms and expanding access to specialized therapies.
Expanded Reimbursement and Access Programs Are Improving Patient Care
Access to advanced therapies remains a critical factor influencing outcomes for patients with short bowel syndrome who require long-term nutritional support. Governments, payers, and healthcare systems are increasingly recognizing the clinical and economic benefits associated with therapies that reduce dependence on parenteral nutrition and intravenous fluids. This trend is reflected by the inclusion of Takeda Canada's REVESTIVE® (teduglutide) within the BC PharmaCare reimbursement framework for eligible pediatric and adult patients with short bowel syndrome. Expanded reimbursement access for GLP-2 analog therapies supports broader adoption of intestinal rehabilitation strategies aimed at improving patient independence and reducing treatment-related complications.
Real-World Evidence Is Highlighting the Burden of Intestinal Failure
The management of short bowel syndrome continues to be challenged by significant clinical complications associated with long-term parenteral support, including infections, metabolic disturbances, and impaired quality of life. Increasing emphasis is being placed on collecting real-world evidence to better characterize patient experiences and identify unmet therapeutic needs. Findings presented by Ironwood Pharmaceuticals at Digestive Disease Week highlighted the substantial burden experienced by patients with short bowel syndrome and intestinal failure, with healthcare providers identifying central line infections, fatigue, and abdominal pain among the most significant challenges. These findings reinforce the urgent need for more effective therapies capable of reducing dependence on chronic supportive interventions.
Next-Generation GLP-2 Therapies Are Reshaping Future Treatment Paradigms
The development of next-generation GLP-2 analog therapies represents one of the most important areas of innovation within the short bowel syndrome market. Pharmaceutical companies are focusing on therapies designed to deliver improved efficacy, longer duration of action, and more convenient dosing schedules compared with existing treatment options. Companies including Ironwood Pharmaceuticals and Zealand Pharma continue to advance novel GLP-2 analogs such as apraglutide and glepaglutide through clinical development programs. These therapies are being positioned as potentially transformative treatment options for patients with short bowel syndrome and intestinal failure by offering enhanced intestinal adaptation benefits alongside reduced treatment burden through less frequent dosing schedules.
Short Bowel Syndrome Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities
The global Short Bowel Syndrome market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Takeda Pharmaceutical Company Limited, Ironwood Pharmaceuticals, Inc. (VectivBio), Zealand Pharma A/S, Hanmi Pharm Co., Ltd., Napo Therapeutics (Jaguar Health), Nestl? S.A., Pfizer Inc., Sanofi S.A., Baxter International Inc., B. Braun Melsungen AG. The Short Bowel Syndrome market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Short Bowel Syndrome industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-
- Growth Short Bowel Syndrome Market size outlook across 3 scenarios- High growth, reference, and Low growth cases
- Market Trends, Drivers, Potential Opportunities, and Challenges faced by Short Bowel Syndrome companies
- Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry
- Detailed SWOT Analysis of global and regional Short Bowel Syndrome markets
- Competitive analysis including business description, product analysis, and financial profiles
- Key country specific analysis detailing key factors shaping the short-term and long-term outlook
- Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements
Leading companies in Short Bowel Syndrome industry include- Takeda Pharmaceutical Company Limited, Ironwood Pharmaceuticals, Inc. (VectivBio), Zealand Pharma A/S, Hanmi Pharm Co., Ltd., Napo Therapeutics (Jaguar Health), Nestl? S.A., Pfizer Inc., Sanofi S.A., Baxter International Inc., B. Braun Melsungen AG. The Short Bowel Syndrome market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.
What to expect in US Short Bowel Syndrome Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034
The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Short Bowel Syndrome market remains one of the strongest-performing segments in the country.
The US Short Bowel Syndrome Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Short Bowel Syndrome market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Short Bowel Syndrome industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.
Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Short Bowel Syndrome markets
Canada's strong Short Bowel Syndrome sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Short Bowel Syndrome market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.
Germany Short Bowel Syndrome Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.
Germany continues to remain the largest Short Bowel Syndrome market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Short Bowel Syndrome population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Short Bowel Syndrome industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Short Bowel Syndrome market outlook.
France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Short Bowel Syndrome sales through 2034
France Short Bowel Syndrome companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.
UK Short Bowel Syndrome Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain
Small high-need consumer segments remain key priority of Short Bowel Syndrome distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.
China Short Bowel Syndrome Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years
China Short Bowel Syndrome market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Short Bowel Syndrome industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Short Bowel Syndrome industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.
India Short Bowel Syndrome Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India
Indian Short Bowel Syndrome market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.
Brazil Short Bowel Syndrome market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities
Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.
Middle East and Africa Short Bowel Syndrome Industry Trends and Perspectives to 2034
According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.
Short Bowel Syndrome Market Segmentation
By Therapy Type
Nutritional Support
Pharmacological Therapeutics
GLP-2 Analogs
Growth Hormones
Symptomatic Treatment Drugs
Surgical Interventions
By Patient Demographics
Pediatric Patients
Adult Patients
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies and Specialty Drugstores
Online / E-pharmacies
Leading Companies in Short Bowel Syndrome Industry (2026)
Takeda Pharmaceutical Company Limited
Ironwood Pharmaceuticals, Inc. (VectivBio)
Zealand Pharma A/S
Hanmi Pharm Co., Ltd.
Napo Therapeutics (Jaguar Health)
Nestl? S.A.
Pfizer Inc.
Sanofi S.A.
Baxter International Inc.
B. Braun Melsungen AG
Countries Included
- North America- US, Canada, Mexico
- Europe- Germany, France, UK, Spain, Italy, Nordics, Others
- Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others
- Latin America- Brazil, Argentina, Others
- Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa
- Get Free print authentication across single, multi, and global licenses
- Free Accompanying excel spreadsheet with complete quantitative data
- Free 2-day consulting support from the lead analyst of the team that developed the report
- Gain clear understanding of current market conditions across 20 countries and plan your decisions accordingly
- Understand competitive profiles of the leading 15 companies in the Electrosurgical Generators industry
- Stay ahead of competition through a detailed analysis of recent market developments
- Make trusted decisions building on our 10-year experience in developing reports on Electrosurgical Generators industry
CHAPTER 1- EXECUTIVE SUMMARY
1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
1.2. Key Industry Highlights, 2026
1.3. Premium Market Insights
1.3.1. Potential Short Bowel Syndrome Market Types and Applications
1.3.2. Fastest Growing Countries Over the forecast period
1.4. Market Scope and Segmentation
1.4.1. Key Market Segments
1.4.2. Key Countries and Regions
1.4.3. Top Companies in the Short Bowel Syndrome Industry
1.5. Macroeconomic and Demographic Outlook
1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
1.5.2. Population Forecast by Country, 2010- 2040
1.5.3. Inflation Trends in Leading Countries
1.6. Impact of Trade Policies, Regulations, and Sustainability
1.6.1. Trade tariffs and localization requirements
1.6.2. ESG and sustainability pressures
1.6.3. Compliance-driven structural changes in the value chain
CHAPTER 2- RESEARCH METHODOLOGY
2.1. Report Coverage
2.2. Secondary Research
2.3. Primary Research
2.4. Data Triangulation
2.5. Market Modeling and Forecasting
CHAPTER 3- GLOBAL SHORT BOWEL SYNDROME MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034
3.1. An Introduction to Global Short Bowel Syndrome Markets in 2026
3.2. Global Historic and Forecast Short Bowel Syndrome Market Size Outlook, USD Million, 2021- 2034
3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
3.4. Market Dynamics
3.4.1. Key Short Bowel Syndrome Market Driving Forces and Their Impact on Market Outlook
3.4.2. Short and Long-Term Trends and Insights Shaping the Future
3.4.3. Potential Short Bowel Syndrome Market Opportunities for Industry Stakeholders
3.4.4. Potential Challenges across Short Bowel Syndrome Value Chain
CHAPTER 4- SHORT BOWEL SYNDROME MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT
4.1. Porter’s Five Forces Analysis
4.1.1. Bargaining Power of Buyers
4.1.2. Bargaining Power of Suppliers
4.1.3. Threat of Substitutes
4.1.4. Threat of New Entrants
4.1.5. Intensity of Competitive Rivalry
4.1.6. Market Attractiveness Analysis by Segment
4.1.7. Market Attractiveness Analysis by Region
4.2. Competitive Landscape
4.2.1 Market Share Analysis of Leading Short Bowel Syndrome Companies
4.2.2 Recent Strategic Developments
4.2.3 Mergers, Acquisitions, and Partnerships
4.2.4 Product Launches and Innovation Trends
4.2.5 Key Success Factors
4.3. Value Chain Analysis
4.3.1. Key Value Chain Segments
4.3.2. Dominant players by value-chain stage
4.4. SWOT Analysis
4.4.1. Key Strengths and Opportunities
4.4.2. Major Weaknesses and Threats
4.5 Technology Roadmap
4.6 Regulatory and Reimbursement Landscape
CHAPTER 5- SHORT BOWEL SYNDROME MARKET OUTLOOK BY SEGMENTS
5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034
5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034
5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034
By Therapy Type
Nutritional Support
Pharmacological Therapeutics
GLP-2 Analogs
Growth Hormones
Symptomatic Treatment Drugs
Surgical Interventions
By Patient Demographics
Pediatric Patients
Adult Patients
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies and Specialty Drugstores
Online / E-pharmacies
CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK
6.1. Base Case Scenario
6.1.1. Definitions and Insights
6.1.2. Market Size Outlook to 2034
6.2. Low Growth Case Scenario
6.2.1. Definitions and Insights
6.2.2. Market Size Outlook to 2034
6.3. High Growth Case Scenario
6.3.1. Definitions and Insights
6.3.2. Market Size Outlook to 2034
CHAPTER 7- NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE ANALYSIS AND OUTLOOK
7.1. North America Short Bowel Syndrome Market Overview, 2026
7.2. Leading Companies Operating in North America
7.3. Key Industry Statistics, 2026
7.4. North America Short Bowel Syndrome Market Trends and Growth Opportunities to 2034
7.5. North America Short Bowel Syndrome Market Size Outlook by Type
7.6. North America Short Bowel Syndrome Market Size Outlook by Application
7.7. North America Short Bowel Syndrome Market Size Outlook by Country
7.8. United States
7.8.1. Key Statistics
7.8.2. The US Short Bowel Syndrome Market Size Outlook, 2021- 2034
7.8.3. Key Market Drivers and Industry Developments in the US Short Bowel Syndrome Companies
7.9. Canada
7.9.1. Key Statistics
7.9.2. Canada Short Bowel Syndrome Market Size Outlook, 2021- 2034
7.9.3. Key Market Drivers and Industry Developments in Canada Short Bowel Syndrome Companies
7.10. Mexico
7.10.1. Key Statistics
7.10.2. Mexico Short Bowel Syndrome Market Size Outlook, 2021- 2034
7.10.3. Key Market Drivers and Industry Developments in Mexico Short Bowel Syndrome Companies
CHAPTER 8- EUROPE SHORT BOWEL SYNDROME MARKET SIZE ANALYSIS AND OUTLOOK
8.1. Europe Short Bowel Syndrome Market Overview, 2026
8.2. Leading Companies Operating in Europe
8.3. Key Industry Statistics, 2026
8.4. Europe Short Bowel Syndrome Market Trends and Growth Opportunities to 2034
8.5. Europe Short Bowel Syndrome Market Size Outlook by Type
8.6. Europe Short Bowel Syndrome Market Size Outlook by Application
8.7. Europe Short Bowel Syndrome Market Size Outlook by Country
8.8. Germany
8.8.1. Key Statistics
8.8.2. Germany Short Bowel Syndrome Market Size Outlook, 2021- 2034
8.8.3. Key Market Drivers and Industry Developments in Germany Short Bowel Syndrome Companies
8.9. France
8.9.1. Key Statistics
8.9.2. France Short Bowel Syndrome Market Size Outlook, 2021- 2034
8.9.3. Key Market Drivers and Industry Developments in France Short Bowel Syndrome Companies
8.10. United Kingdom
8.10.1. Key Statistics
8.10.2. United Kingdom Short Bowel Syndrome Market Size Outlook, 2021- 2034
8.10.3. Key Market Drivers and Industry Developments in the UK Short Bowel Syndrome Companies
8.11. Spain
8.11.1. Key Statistics
8.11.2. Spain Short Bowel Syndrome Market Size Outlook, 2021- 2034
8.11.3. Key Market Drivers and Industry Developments in Spain Short Bowel Syndrome Companies
8.12. Italy
8.12.1. Key Statistics
8.12.2. Italy Short Bowel Syndrome Market Size Outlook, 2021- 2034
8.12.3. Key Market Drivers and Industry Developments in Italy Short Bowel Syndrome Companies
8.13. Rest of Europe
8.13.1. Key Statistics
8.13.2. Rest of Europe Short Bowel Syndrome Market Size Outlook, 2021- 2034
8.13.3. Key Market Drivers and Industry Developments in Rest of Europe Short Bowel Syndrome Companies
CHAPTER 9- ASIA PACIFIC SHORT BOWEL SYNDROME MARKET SIZE ANALYSIS AND OUTLOOK
9.1. Asia Pacific Short Bowel Syndrome Market Overview, 2026
9.2. Leading Companies Operating in Asia Pacific
9.3. Key Industry Statistics, 2026
9.4. Asia Pacific Short Bowel Syndrome Market Trends and Growth Opportunities to 2034
9.5. Asia Pacific Short Bowel Syndrome Market Size Outlook by Type
9.6. Asia Pacific Short Bowel Syndrome Market Size Outlook by Application
9.7. Asia Pacific Short Bowel Syndrome Market Size Outlook by Country
9.8. China
9.8.1. Key Statistics
9.8.2. China Short Bowel Syndrome Market Size Outlook, 2021- 2034
9.8.3. Key Market Drivers and Industry Developments in China Short Bowel Syndrome Companies
9.9. Japan
9.9.1. Key Statistics
9.9.2. Japan Short Bowel Syndrome Market Size Outlook, 2021- 2034
9.9.3. Key Market Drivers and Industry Developments in Japan Short Bowel Syndrome Companies
9.10. India
9.10.1. Key Statistics
9.10.2. India Short Bowel Syndrome Market Size Outlook, 2021- 2034
9.10.3. Key Market Drivers and Industry Developments in India Short Bowel Syndrome Companies
9.11. South Korea
9.11.1. Key Statistics
9.11.2. South Korea Short Bowel Syndrome Market Size Outlook, 2021- 2034
9.11.3. Key Market Drivers and Industry Developments in South Korea Short Bowel Syndrome Companies
9.12. Australia
9.12.1. Key Statistics
9.12.2. Australia Short Bowel Syndrome Market Size Outlook, 2021- 2034
9.12.3. Key Market Drivers and Industry Developments in Australia Short Bowel Syndrome Companies
9.13. Southeast Asia
9.13.1. Key Statistics
9.13.2. Southeast Asia Short Bowel Syndrome Market Size Outlook, 2021- 2034
9.13.3. Key Market Drivers and Industry Developments in Southeast Asia Short Bowel Syndrome Companies
CHAPTER 10- SOUTH AND CENTRAL AMERICA SHORT BOWEL SYNDROME MARKET SIZE ANALYSIS AND OUTLOOK
10.1. South and Central America Short Bowel Syndrome Market Overview, 2026
10.2. Leading Companies Operating in South and Central America
10.3. Key Industry Statistics, 2026
10.4. South and Central America Short Bowel Syndrome Market Trends and Growth Opportunities to 2034
10.5. South and Central America Short Bowel Syndrome Market Size Outlook by Type
10.6. South and Central America Short Bowel Syndrome Market Size Outlook by Application
10.7. South and Central America Short Bowel Syndrome Market Size Outlook by Country
10.8. Brazil
10.8.1. Key Statistics
10.8.2. Brazil Short Bowel Syndrome Market Size Outlook, 2021- 2034
10.8.3. Key Market Drivers and Industry Developments in Brazil Short Bowel Syndrome Companies
10.9. Argentina
10.9.1. Key Statistics
10.9.2. Argentina Short Bowel Syndrome Market Size Outlook, 2021- 2034
10.9.3. Key Market Drivers and Industry Developments in Argentina Short Bowel Syndrome Companies
10.10. Rest of Latin America
10.10.1. Key Statistics
10.10.2. Rest of Latin America Short Bowel Syndrome Market Size Outlook, 2021- 2034
10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America Short Bowel Syndrome Companies
CHAPTER 11- MIDDLE EAST AND AFRICA SHORT BOWEL SYNDROME MARKET SIZE ANALYSIS AND OUTLOOK
11.1. Middle East and Africa Short Bowel Syndrome Market Overview, 2026
11.2. Leading Companies Operating in Middle East and Africa
11.3. Key Industry Statistics, 2026
11.4. Middle East and Africa Short Bowel Syndrome Market Trends and Growth Opportunities to 2034
11.5. Middle East and Africa Short Bowel Syndrome Market Size Outlook by Type
11.6. Middle East and Africa Short Bowel Syndrome Market Size Outlook by Application
11.7. Middle East and Africa Short Bowel Syndrome Market Size Outlook by Country
11.8. Saudi Arabia
11.8.1. Key Statistics
11.8.2. Saudi Arabia Short Bowel Syndrome Market Size Outlook, 2021- 2034
11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia Short Bowel Syndrome Companies
11.9. United Arab Emirates
11.9.1. Key Statistics
11.9.2. The UAE Short Bowel Syndrome Market Size Outlook, 2021- 2034
11.9.3. Key Market Drivers and Industry Developments in the UAE Short Bowel Syndrome Companies
11.10. Africa
11.10.1. Key Statistics
11.10.2. Africa Short Bowel Syndrome Market Size Outlook, 2021- 2034
11.10.3. Key Market Drivers and Industry Developments in Africa Short Bowel Syndrome Companies
CHAPTER 12- COMPANY PROFILES
12.1. Top Companies in Short Bowel Syndrome Industry
Takeda Pharmaceutical Company Limited
Ironwood Pharmaceuticals, Inc. (VectivBio)
Zealand Pharma A/S
Hanmi Pharm Co., Ltd.
Napo Therapeutics (Jaguar Health)
Nestl? S.A.
Pfizer Inc.
Sanofi S.A.
Baxter International Inc.
B. Braun Melsungen AG
12.2. Business Description
12.3. SWOT Profiles
12.4. Products and Services
CHAPTER 13- APPENDIX
Glossary of Terms
Research Methodology & Data Sources
Conclusion & Strategic Recommendations
1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
1.2. Key Industry Highlights, 2026
1.3. Premium Market Insights
1.3.1. Potential Short Bowel Syndrome Market Types and Applications
1.3.2. Fastest Growing Countries Over the forecast period
1.4. Market Scope and Segmentation
1.4.1. Key Market Segments
1.4.2. Key Countries and Regions
1.4.3. Top Companies in the Short Bowel Syndrome Industry
1.5. Macroeconomic and Demographic Outlook
1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
1.5.2. Population Forecast by Country, 2010- 2040
1.5.3. Inflation Trends in Leading Countries
1.6. Impact of Trade Policies, Regulations, and Sustainability
1.6.1. Trade tariffs and localization requirements
1.6.2. ESG and sustainability pressures
1.6.3. Compliance-driven structural changes in the value chain
CHAPTER 2- RESEARCH METHODOLOGY
2.1. Report Coverage
2.2. Secondary Research
2.3. Primary Research
2.4. Data Triangulation
2.5. Market Modeling and Forecasting
CHAPTER 3- GLOBAL SHORT BOWEL SYNDROME MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034
3.1. An Introduction to Global Short Bowel Syndrome Markets in 2026
3.2. Global Historic and Forecast Short Bowel Syndrome Market Size Outlook, USD Million, 2021- 2034
3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
3.4. Market Dynamics
3.4.1. Key Short Bowel Syndrome Market Driving Forces and Their Impact on Market Outlook
3.4.2. Short and Long-Term Trends and Insights Shaping the Future
3.4.3. Potential Short Bowel Syndrome Market Opportunities for Industry Stakeholders
3.4.4. Potential Challenges across Short Bowel Syndrome Value Chain
CHAPTER 4- SHORT BOWEL SYNDROME MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT
4.1. Porter’s Five Forces Analysis
4.1.1. Bargaining Power of Buyers
4.1.2. Bargaining Power of Suppliers
4.1.3. Threat of Substitutes
4.1.4. Threat of New Entrants
4.1.5. Intensity of Competitive Rivalry
4.1.6. Market Attractiveness Analysis by Segment
4.1.7. Market Attractiveness Analysis by Region
4.2. Competitive Landscape
4.2.1 Market Share Analysis of Leading Short Bowel Syndrome Companies
4.2.2 Recent Strategic Developments
4.2.3 Mergers, Acquisitions, and Partnerships
4.2.4 Product Launches and Innovation Trends
4.2.5 Key Success Factors
4.3. Value Chain Analysis
4.3.1. Key Value Chain Segments
4.3.2. Dominant players by value-chain stage
4.4. SWOT Analysis
4.4.1. Key Strengths and Opportunities
4.4.2. Major Weaknesses and Threats
4.5 Technology Roadmap
4.6 Regulatory and Reimbursement Landscape
CHAPTER 5- SHORT BOWEL SYNDROME MARKET OUTLOOK BY SEGMENTS
5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034
5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034
5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034
By Therapy Type
Nutritional Support
Pharmacological Therapeutics
GLP-2 Analogs
Growth Hormones
Symptomatic Treatment Drugs
Surgical Interventions
By Patient Demographics
Pediatric Patients
Adult Patients
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies and Specialty Drugstores
Online / E-pharmacies
CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK
6.1. Base Case Scenario
6.1.1. Definitions and Insights
6.1.2. Market Size Outlook to 2034
6.2. Low Growth Case Scenario
6.2.1. Definitions and Insights
6.2.2. Market Size Outlook to 2034
6.3. High Growth Case Scenario
6.3.1. Definitions and Insights
6.3.2. Market Size Outlook to 2034
CHAPTER 7- NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE ANALYSIS AND OUTLOOK
7.1. North America Short Bowel Syndrome Market Overview, 2026
7.2. Leading Companies Operating in North America
7.3. Key Industry Statistics, 2026
7.4. North America Short Bowel Syndrome Market Trends and Growth Opportunities to 2034
7.5. North America Short Bowel Syndrome Market Size Outlook by Type
7.6. North America Short Bowel Syndrome Market Size Outlook by Application
7.7. North America Short Bowel Syndrome Market Size Outlook by Country
7.8. United States
7.8.1. Key Statistics
7.8.2. The US Short Bowel Syndrome Market Size Outlook, 2021- 2034
7.8.3. Key Market Drivers and Industry Developments in the US Short Bowel Syndrome Companies
7.9. Canada
7.9.1. Key Statistics
7.9.2. Canada Short Bowel Syndrome Market Size Outlook, 2021- 2034
7.9.3. Key Market Drivers and Industry Developments in Canada Short Bowel Syndrome Companies
7.10. Mexico
7.10.1. Key Statistics
7.10.2. Mexico Short Bowel Syndrome Market Size Outlook, 2021- 2034
7.10.3. Key Market Drivers and Industry Developments in Mexico Short Bowel Syndrome Companies
CHAPTER 8- EUROPE SHORT BOWEL SYNDROME MARKET SIZE ANALYSIS AND OUTLOOK
8.1. Europe Short Bowel Syndrome Market Overview, 2026
8.2. Leading Companies Operating in Europe
8.3. Key Industry Statistics, 2026
8.4. Europe Short Bowel Syndrome Market Trends and Growth Opportunities to 2034
8.5. Europe Short Bowel Syndrome Market Size Outlook by Type
8.6. Europe Short Bowel Syndrome Market Size Outlook by Application
8.7. Europe Short Bowel Syndrome Market Size Outlook by Country
8.8. Germany
8.8.1. Key Statistics
8.8.2. Germany Short Bowel Syndrome Market Size Outlook, 2021- 2034
8.8.3. Key Market Drivers and Industry Developments in Germany Short Bowel Syndrome Companies
8.9. France
8.9.1. Key Statistics
8.9.2. France Short Bowel Syndrome Market Size Outlook, 2021- 2034
8.9.3. Key Market Drivers and Industry Developments in France Short Bowel Syndrome Companies
8.10. United Kingdom
8.10.1. Key Statistics
8.10.2. United Kingdom Short Bowel Syndrome Market Size Outlook, 2021- 2034
8.10.3. Key Market Drivers and Industry Developments in the UK Short Bowel Syndrome Companies
8.11. Spain
8.11.1. Key Statistics
8.11.2. Spain Short Bowel Syndrome Market Size Outlook, 2021- 2034
8.11.3. Key Market Drivers and Industry Developments in Spain Short Bowel Syndrome Companies
8.12. Italy
8.12.1. Key Statistics
8.12.2. Italy Short Bowel Syndrome Market Size Outlook, 2021- 2034
8.12.3. Key Market Drivers and Industry Developments in Italy Short Bowel Syndrome Companies
8.13. Rest of Europe
8.13.1. Key Statistics
8.13.2. Rest of Europe Short Bowel Syndrome Market Size Outlook, 2021- 2034
8.13.3. Key Market Drivers and Industry Developments in Rest of Europe Short Bowel Syndrome Companies
CHAPTER 9- ASIA PACIFIC SHORT BOWEL SYNDROME MARKET SIZE ANALYSIS AND OUTLOOK
9.1. Asia Pacific Short Bowel Syndrome Market Overview, 2026
9.2. Leading Companies Operating in Asia Pacific
9.3. Key Industry Statistics, 2026
9.4. Asia Pacific Short Bowel Syndrome Market Trends and Growth Opportunities to 2034
9.5. Asia Pacific Short Bowel Syndrome Market Size Outlook by Type
9.6. Asia Pacific Short Bowel Syndrome Market Size Outlook by Application
9.7. Asia Pacific Short Bowel Syndrome Market Size Outlook by Country
9.8. China
9.8.1. Key Statistics
9.8.2. China Short Bowel Syndrome Market Size Outlook, 2021- 2034
9.8.3. Key Market Drivers and Industry Developments in China Short Bowel Syndrome Companies
9.9. Japan
9.9.1. Key Statistics
9.9.2. Japan Short Bowel Syndrome Market Size Outlook, 2021- 2034
9.9.3. Key Market Drivers and Industry Developments in Japan Short Bowel Syndrome Companies
9.10. India
9.10.1. Key Statistics
9.10.2. India Short Bowel Syndrome Market Size Outlook, 2021- 2034
9.10.3. Key Market Drivers and Industry Developments in India Short Bowel Syndrome Companies
9.11. South Korea
9.11.1. Key Statistics
9.11.2. South Korea Short Bowel Syndrome Market Size Outlook, 2021- 2034
9.11.3. Key Market Drivers and Industry Developments in South Korea Short Bowel Syndrome Companies
9.12. Australia
9.12.1. Key Statistics
9.12.2. Australia Short Bowel Syndrome Market Size Outlook, 2021- 2034
9.12.3. Key Market Drivers and Industry Developments in Australia Short Bowel Syndrome Companies
9.13. Southeast Asia
9.13.1. Key Statistics
9.13.2. Southeast Asia Short Bowel Syndrome Market Size Outlook, 2021- 2034
9.13.3. Key Market Drivers and Industry Developments in Southeast Asia Short Bowel Syndrome Companies
CHAPTER 10- SOUTH AND CENTRAL AMERICA SHORT BOWEL SYNDROME MARKET SIZE ANALYSIS AND OUTLOOK
10.1. South and Central America Short Bowel Syndrome Market Overview, 2026
10.2. Leading Companies Operating in South and Central America
10.3. Key Industry Statistics, 2026
10.4. South and Central America Short Bowel Syndrome Market Trends and Growth Opportunities to 2034
10.5. South and Central America Short Bowel Syndrome Market Size Outlook by Type
10.6. South and Central America Short Bowel Syndrome Market Size Outlook by Application
10.7. South and Central America Short Bowel Syndrome Market Size Outlook by Country
10.8. Brazil
10.8.1. Key Statistics
10.8.2. Brazil Short Bowel Syndrome Market Size Outlook, 2021- 2034
10.8.3. Key Market Drivers and Industry Developments in Brazil Short Bowel Syndrome Companies
10.9. Argentina
10.9.1. Key Statistics
10.9.2. Argentina Short Bowel Syndrome Market Size Outlook, 2021- 2034
10.9.3. Key Market Drivers and Industry Developments in Argentina Short Bowel Syndrome Companies
10.10. Rest of Latin America
10.10.1. Key Statistics
10.10.2. Rest of Latin America Short Bowel Syndrome Market Size Outlook, 2021- 2034
10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America Short Bowel Syndrome Companies
CHAPTER 11- MIDDLE EAST AND AFRICA SHORT BOWEL SYNDROME MARKET SIZE ANALYSIS AND OUTLOOK
11.1. Middle East and Africa Short Bowel Syndrome Market Overview, 2026
11.2. Leading Companies Operating in Middle East and Africa
11.3. Key Industry Statistics, 2026
11.4. Middle East and Africa Short Bowel Syndrome Market Trends and Growth Opportunities to 2034
11.5. Middle East and Africa Short Bowel Syndrome Market Size Outlook by Type
11.6. Middle East and Africa Short Bowel Syndrome Market Size Outlook by Application
11.7. Middle East and Africa Short Bowel Syndrome Market Size Outlook by Country
11.8. Saudi Arabia
11.8.1. Key Statistics
11.8.2. Saudi Arabia Short Bowel Syndrome Market Size Outlook, 2021- 2034
11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia Short Bowel Syndrome Companies
11.9. United Arab Emirates
11.9.1. Key Statistics
11.9.2. The UAE Short Bowel Syndrome Market Size Outlook, 2021- 2034
11.9.3. Key Market Drivers and Industry Developments in the UAE Short Bowel Syndrome Companies
11.10. Africa
11.10.1. Key Statistics
11.10.2. Africa Short Bowel Syndrome Market Size Outlook, 2021- 2034
11.10.3. Key Market Drivers and Industry Developments in Africa Short Bowel Syndrome Companies
CHAPTER 12- COMPANY PROFILES
12.1. Top Companies in Short Bowel Syndrome Industry
Takeda Pharmaceutical Company Limited
Ironwood Pharmaceuticals, Inc. (VectivBio)
Zealand Pharma A/S
Hanmi Pharm Co., Ltd.
Napo Therapeutics (Jaguar Health)
Nestl? S.A.
Pfizer Inc.
Sanofi S.A.
Baxter International Inc.
B. Braun Melsungen AG
12.2. Business Description
12.3. SWOT Profiles
12.4. Products and Services
CHAPTER 13- APPENDIX
Glossary of Terms
Research Methodology & Data Sources
Conclusion & Strategic Recommendations
